INDUSTRY members are up in
arms over the Federal
Government’s decision to reject the
recommendation to reinstate the
‘$10 million rule’.
“This was the government’s
opportunity to shut down the
deferral issue once and for all,” CE
of AstraZeneca Australia, Mark
Fladrich told media.
The $10 million rule basically
meant that drugs which had received
a positive recommendation by an
independent committee for PBS
listing and which would cost less
than $10 million per annum, could
bypass the Cabinet approval process.
The Senate inquiry kicked-off
after the Government’...
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 14 Aug 12
Pharmacy Daily is Australia's favourite online publication dedicated to the pharmacy industry. The publication launched in March 2007 and is distributed every day by email to pharmacists across the country. MORE